RLVT 9-01
Alternative Names: RLVT-9-01Latest Information Update: 02 Nov 2020
At a glance
- Originator University of California, Riverside
- Developer Releviate Therapeutics
- Class Analgesics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuropathic pain
Most Recent Events
- 02 Nov 2020 Pharmacodynamics data from preclinical studies in Neuropathic pain released by Releviate Therapeutics (Releviate Therapeutics website, November 2020).
- 28 Oct 2020 Releviate Therapeutics in-licenses RLVT 9-01 from the University of California, Riverside before October 2020
- 28 Oct 2020 Preclinical trials in Neuropathic pain in USA (Parenteral) before October 2020